It is China's first and only domestic "three-in-one" single-tablet combination Class 1 new drug for HIV treatment. As a new-generation non-nucleoside combination, it has been included in the national medical insurance catalog through price negotiations and recommended by the Chinese Guidelines for the Diagnosis and Treatment of AIDS (2024 Edition).
Drug name: Aitribond 150 mg, 300 mg, 300 mg film-coated tablets.
Storage: Protect from light. Store at no more than 30℃. Keep container tightly closed.
Ingredients: Each tablet contains 150 mg of ainuovirine (ANV), 300 mg of lamivudine (3TC) and
300 mg of tenofovir disoproxil fumarate (TDF).
Description: white or off-white tablet.
Indications: indicated for use in combination with nucleoside antiretroviral drugs, for treating naïve HIV-1 infected adults.
Shelf life: 36 months
The incidence of CNS side effects, rash and gastrointestinal adverse reactions can be significantly reduced, with significantly improved patients' tolerance.
It has little effect on lipid metabolism while reducing the risk of cardiovascular and cerebrovascular diseases, fatty liver and other diseases.
It has low hepatotoxicity and can significantly reduce liver function impairment.
It is metabolized by CYP2C19 pathway and effectively reduces the risk of DDIs.
Potent viral suppression with sustained anti-HIV efficacy.
Excellent efficacy in patients with high or low baseline viral load.
Rapid increase of CD4+ cells with continuous improvement of immune system.
